Client Fortrea Completes Sale of Endpoint Clinical and Patient Access Businesses to Arsenal Capital Partners

Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO) that helps make life changing therapies for patients, has finalized the sale of its Endpoint Clinical (Endpoint) and Fortrea Patient Access (FPA) businesses to Arsenal Capital Partners, a leading private equity firm specializing in building technology-rich healthcare and industrial growth companies. Smith Anderson advised Fortrea on the deal.

This strategic move allows Fortrea to focus on its core CRO business that provides phase I-IV clinical trial management, clinical pharmacology and consulting services with added financial flexibility. The services provided by Endpoint Clinical and Fortrea Patient Access are key areas in the pharmaceutical industry where Arsenal has deep scientific and technical knowledge, according to a press release.

Endpoint Clinical specializes in Randomization and Trial Supply Management (RTSM) solutions to biopharmaceutical and CRO customers, particularly in complex and late-stage clinical trials, and has supported over 1,750 clinical trials involving 875,000 patients in 90 countries over the past 15 years.

Fortrea Patient Access is a leader in HUB services and patient access for the biopharmaceutical industry for over 30 years. It offers comprehensive patient support, product access, affordability and adherence solutions and recently expanded with a non-commercial specialty pharmacy to enhance distribution of cold-chain and ambient products. FPA currently supports over 2.5 million patients and 100 unique brands across more than 25 disease areas.

Smith Anderson M&A attorneys Gerald Roach, James Jolley, Amy Batten, Jason Martinez, Hunter Huffman and Marshall Newman led the team that advised Fortrea on this transaction.

The full press release issued by Fortrea can be viewed here.